Eledon Pharmaceuticals, Inc.

NasdaqCM:ELDN Stock Report

Market Cap: US$288.5m

Eledon Pharmaceuticals Management

Management criteria checks 2/4

Eledon Pharmaceuticals' CEO is DA Gros, appointed in Sep 2020, has a tenure of 4.33 years. total yearly compensation is $2.55M, comprised of 21.9% salary and 78.1% bonuses, including company stock and options. directly owns 0.015% of the company’s shares, worth $43.48K. The average tenure of the management team and the board of directors is 3.8 years and 6.1 years respectively.

Key information

DA Gros

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage21.9%
CEO tenure4.3yrs
CEO ownership0.02%
Management average tenure3.8yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Mar 22
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Dec 05
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Aug 10
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Apr 27
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Jan 05
Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Eledon adds 10% as FDA clears clinical trial for kidney disease candidate

Sep 06

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Aug 31
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Eledon gets FDA nod to start trial of organ rejection preventing therapy

Aug 01

Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients

Jul 18

Eledon gives update on development strategy for AT-1501 in renal transplantation

Apr 26

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Apr 14
Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Feb 21
What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Dec 30
Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Novus Therapeutics (NVUS) Investor Presentation - Slideshow

Dec 18

Novus Therapeutics EPS misses by $3.76

Nov 16

Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease

Nov 02

CEO Compensation Analysis

How has DA Gros's remuneration changed compared to Eledon Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$25m

Jun 30 2024n/an/a

-US$89m

Mar 31 2024n/an/a

-US$129m

Dec 31 2023US$3mUS$559k

-US$117m

Sep 30 2023n/an/a

-US$145m

Jun 30 2023n/an/a

-US$145m

Mar 31 2023n/an/a

-US$89m

Dec 31 2022US$1mUS$533k

-US$88m

Sep 30 2022n/an/a

-US$38m

Jun 30 2022n/an/a

-US$38m

Mar 31 2022n/an/a

-US$36m

Dec 31 2021US$748kUS$504k

-US$35m

Sep 30 2021n/an/a

-US$32m

Jun 30 2021n/an/a

-US$28m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$7mUS$150k

-US$23m

Compensation vs Market: DA's total compensation ($USD2.55M) is above average for companies of similar size in the US market ($USD1.38M).

Compensation vs Earnings: DA's compensation has increased whilst the company is unprofitable.


CEO

DA Gros (52 yo)

4.3yrs

Tenure

US$2,553,153

Compensation

Dr. David-Alexandre C. Gros, also known as DA, M.D., Ph D., serves as Chief Executive Officer and Non-Independent Director at Eledon Pharmaceuticals, Inc. since September 09, 2020. Dr. Gros served as an ad...


Leadership Team

NamePositionTenureCompensationOwnership
David-Alexandre Gros
CEO & Non Independent Director4.3yrsUS$2.55m0.015%
$ 43.5k
Steven Perrin
President4.3yrsUS$1.54m0.0017%
$ 4.8k
Paul Little
Chief Financial Officer3.8yrsUS$1.32m0.017%
$ 48.3k
John Herberger
Vice President of Technical Operations2.7yrsno datano data
Bryan Smith
General Counsel3.8yrsUS$1.68m0%
$ 0
David Hovland
Chief Regulatory Officer3.8yrsno datano data
Eliezer Katz
Chief Medical Officer1.3yrsno datano data

3.8yrs

Average Tenure

55yo

Average Age

Experienced Management: ELDN's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
David-Alexandre Gros
CEO & Non Independent Director4.3yrsUS$2.55m0.015%
$ 43.5k
Steven Perrin
President4.3yrsUS$1.54m0.0017%
$ 4.8k
Keith Katkin
Independent Chairman of the Board7.7yrsUS$1.52m0.0011%
$ 3.3k
John McBride
Independent Director7.7yrsUS$371.82k0%
$ 0
James Robinson
Independent Director1.3yrsUS$201.79kno data
June Lee
Independent Director4.1yrsUS$374.44k0%
$ 0
Hamid Djalilian
Member of Scientific Advisory Board6.1yrsno datano data
Paola Marchisio
Member of Scientific Advisory Board6.1yrsno datano data
Tal Marom
Member of Scientific Advisory Board6.1yrsno datano data
Michael Pichichero
Member of Scientific Advisory Board6.1yrsno datano data
Anne Schilder
Member of Scientific Advisory Board6.1yrsno datano data
Seth Pranksy
Member of Scientific Advisory Board6.1yrsno datano data

6.1yrs

Average Tenure

56yo

Average Age

Experienced Board: ELDN's board of directors are considered experienced (6.1 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 09:16
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Eledon Pharmaceuticals, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Alethia YoungCantor Fitzgerald & Co.
Pete StavropoulosCantor Fitzgerald & Co.